NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma

Withdrawn

Conditions: Hepatocellular Cancer
Hepatocellular Carcinoma

First Posted Date: 2018-11-21

Last Posted Date: 2020-03-26

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT03748927

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Phase 1

Recruiting

Conditions: Rectal Cancer
Colon Cancer
Gastric Cancer
Gastrointestinal Cancer
Pancreatic Cancer

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Aldesleukin
Biological: anti-KRAS G12D mTCR PBL

First Posted Date: 2018-11-19

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT03745326

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Withdrawn

Conditions: Refractory Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia

Interventions: Drug: Azacitidine
Drug: Pevonedistat

First Posted Date: 2018-11-19

Last Posted Date: 2023-06-27

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT03745352

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Phase 2

Suspended

Conditions: Refractory B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Recurrent B Acute Lymphoblastic Leukemia

Interventions: Biological: Blinatumomab
Biological: Inotuzumab Ozogamicin

First Posted Date: 2018-11-14

Last Posted Date: 2025-05-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 64

Registration Number: NCT03739814

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

and more 269 locations

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Recruiting

Conditions: Refractory Solid Tumors
Other Neoplasms Solid Tumors
Solid Tumor
Malignant Solid Tumors
Pediatric Solid Tumor

First Posted Date: 2018-11-14

Last Posted Date: 2025-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10000

Registration Number: NCT03739827

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Ibrutinib
Biological: Obinutuzumab
Other: Observation Activity
Drug: Venetoclax

First Posted Date: 2018-11-13

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 465

Registration Number: NCT03737981

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

and more 856 locations

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

Phase 1

Active, not recruiting

Conditions: Stage II Cervical Cancer AJCC v8
Cervical Adenocarcinoma
Cervical Squamous Cell Carcinoma
Stage IVA Cervical Cancer AJCC v8
Cervical Adenosquamous Carcinoma
Stage IIA Cervical Cancer AJCC v8
Stage IIA2 Cervical Cancer AJCC v8
Stage IIB Cervical Cancer AJCC v8
Stage IB2 Cervical Cancer AJCC v8
Stage IIIB Cervical Cancer AJCC v8

Interventions: Drug: Atezolizumab
Radiation: Brachytherapy
Drug: Cisplatin
Radiation: Radiation Therapy

First Posted Date: 2018-11-13

Last Posted Date: 2025-03-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT03738228

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Women and Infants Hospital, Providence, Rhode Island, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 13 locations

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8
Lung Non-Squamous Non-Small Cell Carcinoma

Interventions: Drug: Crizotinib
Drug: Alectinib
Drug: Brigatinib
Drug: Ceritinib
Drug: Lorlatinib
Drug: Carboplatin
Drug: Ensartinib
Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2018-11-13

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT03737994

Locations: 🇺🇸
Macomb Hematology Oncology PC, Warren, Michigan, United States
🇺🇸
Kaiser Permanente-Richmond, Richmond, California, United States
🇺🇸
Carle Cancer Center, Urbana, Illinois, United States

and more 486 locations

Optimization of Collection Methods for Studies of the Human Microbiota

Withdrawn

Conditions: Microbial Composition

First Posted Date: 2018-11-06

Last Posted Date: 2020-10-28

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT03731702

Locations: 🇺🇸
NIH NCI Shady Grove, Rockville, Maryland, United States

Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial

Phase 3

Completed

Conditions: Human Papillomavirus-Related Cervical Carcinoma

Interventions: Biological: Recombinant Human Papillomavirus Bivalent Vaccine
Biological: Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine

First Posted Date: 2018-11-02

Last Posted Date: 2024-07-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1240

Registration Number: NCT03728881

Locations: 🇨🇷
Agencia Costarricense de Investigaciones Biomédicas (ACIB), Liberia, Guanacaste, Costa Rica

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy